報價延遲最少15分鐘:2026/03/10 00:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
194.95 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
6.54/13.22
|
|
企業價值
629.81B
|
| 資產負債 |
|
每股賬面淨值
31.38
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
58.74B
|
|
每股收益
29.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales. |
